Celyad Oncology SA CLYYF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 154.69% | 137.41% | 119.62% | 61.00% | 16.19% |
| Total Depreciation and Amortization | -115.12% | -90.79% | -70.39% | -51.31% | -38.31% |
| Total Amortization of Deferred Charges | -25.22% | -25.22% | -25.22% | -6.01% | 19.79% |
| Total Other Non-Cash Items | -150,503.85% | -10,725.00% | -5,282.38% | -2,940.79% | -98.73% |
| Change in Net Operating Assets | -1,824.42% | -1,154.19% | -797.23% | 45.93% | 96.76% |
| Cash from Operations | 10.61% | -9.85% | -27.11% | 13.29% | 36.51% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | 21,554.32% | 21,554.32% | 21,554.32% | 7,854.05% | -42.35% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 100.00% | 100.00% |
| Cash from Investing | 21,554.32% | 7,516.49% | 3,251.84% | 520.73% | 102.21% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 66.24% | 44.75% | 24.55% | 6.60% | -15.44% |
| Issuance of Common Stock | -- | -- | -- | -89.83% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -38.48% | -73.23% | -82.38% | -74.50% | -63.61% |
| Cash from Financing | 128.50% | -16.68% | -49.28% | -85.08% | -94.23% |
| Foreign Exchange rate Adjustments | 393.75% | 331.58% | 288.37% | 213.64% | -- |
| Miscellaneous Cash Flow Adjustments | -- | 500.00% | 0.00% | 100.00% | 100.00% |
| Net Change in Cash | 86.83% | 59.33% | 12.39% | -396.18% | -536.51% |